Showing results (81-90 of 127) with videos related to
Sort By:
Pageof 13
Cell Reports|April 8, 2016
Suppression of Type I Interferon Signaling Overcomes Oncogene-Induced Senescence and Mediates Melanoma Development and ProgressionYuliya V Katlinskaya, Kanstantsin V Katlinski, Qiujing Yu, et al.Journal for Immunotherapy of Cancer|July 22, 2024
Subcutaneous checkpoint inhibition is equivalent to systemic delivery when combined with nelitolimod delivered via pressure-enabled drug delivery for depletion of intrahepatic myeloid-derived suppressor cells and control of liver metastasesChandra C Ghosh, Lauren Cournoyer, Yujia Liu, et al.Journal for Immunotherapy of Cancer|October 19, 2023
Identification of tumor-intrinsic drivers of immune exclusion in acral melanomaRyan C Augustin, Sarah Newman, Aofei Li, et al.Biorxiv : the Preprint Server for Biology|September 4, 2023
Identification of tumor-intrinsic drivers of immune exclusion in acral melanomaRyan C Augustin, Sarah Newman, Aofei Li, et al.Cancer Chemotherapy and Pharmacology|October 8, 2025
A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti-PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation resultsJayesh Desai, Sanjeev Deva, Bo Gao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2020
IL15 Stimulation with TIGIT Blockade Reverses CD155-mediated NK-Cell Dysfunction in MelanomaJoe-Marc Chauvin, Mignane Ka, Ornella Pagliano, et al.Cancer Discovery|July 30, 2021
Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic MelanomaAntoni Ribas, Theresa Medina, John M Kirkwood, et al.Cancer Chemotherapy and Pharmacology|January 22, 2025
Phase I trial of ATR inhibitor elimusertib with FOLFIRI in advanced or metastatic gastrointestinal malignancies (ETCTN 10406)Anuradha Krishnamurthy, Hong Wang, John C Rhee, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 2, 2022
Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid TumorsDiwakar Davar, Roberta Zappasodi, Hong Wang, et al.Journal of Inherited Metabolic Disease|February 13, 2020
Expanding the molecular and clinical phenotypes of FUT8-CDGBobby G Ng, Hassan Dastsooz, Mohammad Silawi, et al.Pageof 13